Posted by Michael Wonder on 23 May 2023
Centessa Pharmaceuticals receives fast track designation from the US FDA for SerpinPC for haemophilia B
22 May 2023 - Centessa Pharmaceuticals today announced that the US FDA has granted fast track designation to SerpinPC, an investigational novel inhibitor of activated protein C (APC) being developed for the treatment of haemophilia B, with or without inhibitors.
SerpinPC is a subcutaneously administered novel inhibitor of APC being developed as a potential treatment for haemophilia, regardless of severity or inhibitor status, and which may also be developed to prevent bleeding associated with other bleeding disorders.
